SCHEMBL5745570

SCHEMBL5745570

COC(=O)/C(O)=C/c1cccnc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.65
LMNA P02545 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
ALDH1A1 P00352 3/20 0.50
CYP11B2 P19099 2/20 0.50
CYP19A1 P11511 1/20 0.50
KDM4E B2RXH2 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MAPK1 P28482 2/20 0.47
JUN P05412 1/20 0.47
NFKB1 P19838 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
CYP1A1 P04798 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP1B1 Q16678 2/20 0.46
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745572 1.00 MAPT (0.65) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL3225999 0.87 MAPT (0.78) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL5747715 0.83 KMT2A (0.54) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL5747718 0.83 KMT2A (0.54) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL10991105 0.81 MAPT (0.74) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL13451361 0.81 SMN1; SMN2 (0.62) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL10373700 0.81 MAPT (0.74) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL1221498 0.81 MEN1 (0.52) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL259947 0.79 MAPT (0.67) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2
SCHEMBL9040802 0.79 LMNA (0.55) MAPTLMNASMN1; SMN2ALDH1A1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664040-A1 GYRASE INHIBITORS PFIZER INC. (US) 2006-06-07 EP disclosed
US-6984652-B2 Gyrase inhibitors WARNER-LAMBERT COMPANY LLC (US) 2006-01-10 US disclosed
US-20050250823-A1 Gyrase inhibitors YAGER KRAIG 2005-11-10 US disclosed
WO-2005026162-A1 GYRASE INHIBITORS PFIZER INC. (US) 2005-03-24 WO disclosed
US-20050054697-A1 Gyrase inhibitors PFIZER INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054697-A1 Gyrase inhibitors TOP1, TOP2A, TOP2B MAPT 3874/4885LMNA 881/4885SMN1; SMN2 4219/4885
US-20050250823-A1 Gyrase inhibitors TOP1, TOP2A, TOP2B MAPT 3874/4885LMNA 881/4885SMN1; SMN2 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.